An Open label, balanced, randomized, two-treatment, twoperiod, two-sequence, single dose, crossover, oral,bioequivalence study of Esomeprazole 40 mg MUPS tablets ofSunGlow Lifescience Private Ltd with Nexium mups 40 mggastro resistant tablets (Esomeprazole) of Grunenthal GmbH in healthy adult human subjects under fasting conditions. - NIL
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Sitagliptin 100 mg & Metformin Hydrochloride 1000 mg (extended release) Tablets of SunGlow Lifescience Private Ltd., in comparison with Janumet XR 100 mg/ 1000 mg tablets {Sitagliptin and metformin HCl (extended release) tablets 100 mg/1,000 mg} of Merck Sharp & Dohme Corp in healthy, adult, human subjects under fed conditions.
An open label balanced randomized two treatment two period two sequence single oral dose crossover bioequivalence study of Sitagliptin 50 mg Metformin Hydrochloride 500 mg extended release Tablets of SunGlow Lifescience Private Ltd in comparison with Janumet XR 50 mg 500 mg tablets Sitagliptin and metformin HCl extended release tablets 50 mg 500 mg of Merck Sharp Dohme Corp in healthy adult human subjects under fasting conditions
100 Clinical Results associated with SunGlow Lifescience Pvt Ltd.
0 Patents (Medical) associated with SunGlow Lifescience Pvt Ltd.
100 Deals associated with SunGlow Lifescience Pvt Ltd.
100 Translational Medicine associated with SunGlow Lifescience Pvt Ltd.